<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sacrosidase: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sacrosidase: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Sacrosidase: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10253" href="/d/html/10253.html" rel="external">see "Sacrosidase: Drug information"</a> and <a class="drug drug_patient" data-topicid="12112" href="/d/html/12112.html" rel="external">see "Sacrosidase: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F219729"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Sucraid</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1061975"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Sucrase Deficiency, Treatment Agent</span></li></ul></div>
<div class="block dop drugH1Div" id="F219737"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="354cce4f-bdcb-474e-a4e7-e48428276379">Congenital sucrose-isomaltase deficiency or sucrase deficiency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Congenital sucrose-isomaltase deficiency or sucrase deficiency: </b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Approximately half of the dose should be administered before the meal or snack and the remainder administered during the meal or snack. Dose may be measured by volume (mL) or drop count method from the Sucraid container tip in which case 1 mL = 28 drops.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children ≤15 kg: Oral: 8,500 units (1 mL = 28 drops from Sucraid container tip) per meal or snack; in reports, the youngest patients at sacrosidase therapy initiation have been 5 and 6 months of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26163121','lexi-content-ref-9932843']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26163121','lexi-content-ref-9932843'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children &gt;15 kg and Adolescents: Oral: 17,000 units (2 mL = 56 drops from Sucraid container tip) per meal or snack.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51192711"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51192712"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F219732"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10253" href="/d/html/10253.html" rel="external">see "Sacrosidase: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d0be5795-c15b-4d15-a577-366268098b21">Congenital sucrase-isomaltase deficiency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;display:inline">
<b>Congenital sucrase-isomaltase deficiency (CSID):</b>
<b>Oral:</b> 17,000 units (2 mL) per meal or snack.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50989955"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987273"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F219705"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache, insomnia, nervousness</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, constipation, diarrhea, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Bronchospasm, hypersensitivity reaction, wheezing</p></div>
<div class="block coi drugH1Div" id="F219717"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to yeast, yeast products, glycerin (glycerol), or papain</p></div>
<div class="block war drugH1Div" id="F219702"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Hypersensitivity reactions: Hypersensitivity reactions to sacrosidase, including bronchospasm, have been reported. Administer initial doses in a setting where acute hypersensitivity reactions may be treated within a few minutes. Skin testing for hypersensitivity may be performed prior to administration to identify patients at risk.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Diabetes mellitus: Use with caution in patients with diabetes; sacrosidase enables absorption of fructose and glucose.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Dosage form specific issues</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Papain: Product may contain papain. Severe hypersensitivity reactions, including anaphylaxis, have been observed with papain exposure. Tachycardia and hypotension, in association with some papain-induced hypersensitivity reactions, has also been observed. In addition, inconclusive data suggests a possible cross-sensitivity may exist between patients with natural rubber latex hypersensitivity and papaya, the source of papain.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878626"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Oral solution contains 50% glycerol. </p></div>
<div class="block foc drugH1Div" id="F219712"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sucraid: 8500 units/mL (2 mL, 118 mL) [contains papain]</p></div>
<div class="block geq drugH1Div" id="F219698"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F219720"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Sucraid Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">8500 units/mL (per mL): $45.97</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block accres drugH1Div" id="F11234325"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Sucraid is not available in retail pharmacies or via mail-order pharmacies. To obtain the product, please refer to http://www.sucraid.net/how-to-order-sucraid or call 1-866-740-2743.</p></div>
<div class="block admp drugH1Div" id="F52613836"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Dilute dose prior to administration. Approximately <sup>1</sup>/<sub>2</sub> of the dose may be administered before each meal or snack, and the remainder of the dose during the meal or snack (may help to preserve sacrosidase activity and allow for better sucrose absorption). Do not administer with fruit juices (acidic environment may reduce enzyme activity) or warm or hot food/liquids (heat may lower potency of enzyme). Rinse measuring scoop with water after use.</p></div>
<div class="block adm drugH1Div" id="F219714"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Dilute dose in 120 mL of cold or room temperature water or milk and mix well; avoid dissolving in fruit juices or warm or hot food/liquids. Administer one-half of dose at beginning of each meal and snack and remainder during meal or snack. Measure dosage from multiple-dose bottle with measuring scoop provided or by drop count method (1 mL equals 28 drops from the bottle tip); also available as 2 mL single-use container.</p></div>
<div class="block sts drugH1Div" id="F219726"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Multidose bottle: Store under refrigeration at 2°C to 8°C (36°F to 46°F); protect from heat. Protect from light. After initial opening, discard any unused product after 4 weeks.</p>
<p style="text-indent:-2em;margin-left:2em;">Single-use container: Store under refrigeration at 2°C to 8°C (36°F to 46°F); protect from light. May be removed from the refrigerator and stored at 15°C to 25°C (59°F to 77°F) for up to 3 days (72 hours).</p></div>
<div class="block usep drugH1Div" id="F53568765"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Replacement therapy in congenital sucrase-isomaltase deficiency (CSID) (FDA approved in pediatric patients [age not specified] and adults)</p></div>
<div class="block cyt drugH1Div" id="F13300019"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F219707"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block foi drugH1Div" id="F219727"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">May be inactivated or denatured if administered with fruit juice or warm or hot food/liquids. Isomaltase deficiency is not addressed by supplementation of sacrosidase. Management: Administer with 2-4 oz of water, milk, or formula. Because isomaltase deficiency is not addressed by supplementation of sacrosidase, adherence to a low-starch diet may be required.</p></div>
<div class="block dic drugH1Div" id="F9614165"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Do not take with fruit juices. Because isomaltase deficiency is not addressed by supplementation of sacrosidase, adherence to a low-starch diet may be required.</p></div>
<div class="block pri drugH1Div" id="F219721"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted. Use is not expected to cause fetal harm when used during pregnancy; administer to a pregnant woman only when indicated. </p></div>
<div class="block mopp drugH1Div" id="F53568766"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Congenital sucrase-isomaltase deficiency symptomatology: Diarrhea, abdominal pain, gas, and abdominal distention/bloating from excessive fermentation of undigested carbohydrates</p></div>
<div class="block pha drugH1Div" id="F219701"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Sacrosidase is a naturally-occurring gastrointestinal enzyme derived from baker's yeast (<i>Saccharomyces cerevisiae</i>) which breaks down the disaccharide sucrose to its monosaccharide components. Hydrolysis is necessary to allow absorption of these nutrients.</p></div>
<div class="block phk drugH1Div" id="F219716"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Amino acids </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: GI tract to individual amino acids</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6875321"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Sucraid</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Sucraid</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Sucraid</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-7943998">
<a name="7943998"></a>Blanco C, Carrillo T, Castillo R, et al, “Latex Allergy: Clinical Features and Cross-Reactivity With Fruits,” <i>Ann Allergy</i>, 1994, 73(4):309-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacrosidase-pediatric-drug-information/abstract-text/7943998/pubmed" id="7943998" target="_blank">7943998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12859455">
<a name="12859455"></a>Focke M, Hemmer W, Wohrl S, et al, “Cross-reactivity Between <i>Ficus benjamina</i> Latex and Fig Fruit in Patients With Clinical Fig Allergy,” <i>Clin Exp Allergy</i>, 2003, 33(7):971-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacrosidase-pediatric-drug-information/abstract-text/12859455/pubmed" id="12859455" target="_blank">12859455</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3234762">
<a name="3234762"></a>Freye HB, “Papain Anaphylaxis: A Case Report,” <i>Allergy Proc</i>, 1988, 9(5):571-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacrosidase-pediatric-drug-information/abstract-text/3234762/pubmed" id="3234762" target="_blank">3234762</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12866323">
<a name="12866323"></a>Isola S, Ricciardi L, Saitta S, et al, “Latex Allergy and Fruit Cross-Reaction in Subjects Who Are Nonatopic,” <i>Allergy Asthma Proc</i>, 2003, 24(3):193-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacrosidase-pediatric-drug-information/abstract-text/12866323/pubmed" id="12866323" target="_blank">12866323</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26163121">
<a name="26163121"></a>Puntis JW, Zamvar V. Congenital sucrase-isomaltase deficiency: diagnostic challenges and response to enzyme replacement therapy. <i>Arch Dis Child</i>. 2015;100(9):869-871.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacrosidase-pediatric-drug-information/abstract-text/26163121/pubmed" id="26163121" target="_blank">26163121</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sucraid.1">
<a name="Sucraid.1"></a>Sucraid (sacrosidase) oral solution [prescribing information]. Vero Beach, FL: QOL Medical LLC; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9932843">
<a name="9932843"></a>Treem WR, McAdams L, Stanford L, et al, “Sacrosidase Therapy for Congenital Sucrose-Isomaltase Deficiency,” <i>J Pediatr Gastroenterol Nutr</i>, 1999, 28(2):137-42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacrosidase-pediatric-drug-information/abstract-text/9932843/pubmed" id="9932843" target="_blank">9932843</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12777 Version 123.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
